Finance And Related Services Tenders

Medicines with the Active Ingredient Erenumab (Atc: N02cd01)

Medicines with the Active Ingredient Natalizumab (Atc: L04ag03)

Medicines with the Active Ingredient Fremanezumab (Atc: N02cd03)

Medicines with the Active Ingredient Combination Elbasvir and Grazoprevir (atc: J05ap54)

Medicines with the Active Ingredient Galcanezumab (atc: N02cd02)

Medicines with the Active Ingredient Combination Sofosbuvir and Velpatasvir (atc: J05ap55)

Approval Procedure for the Contract for Special Care According to Section 140A Sgb V to Improve Post-Inpatient Treatment Using the Example of Cardiac Diseases "Cardiolotse

Order Announcement - Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130 a Paragraph 8 Sgb V for Drugs with the Active Ingredient Bimekizumab

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V (Open House Model)

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V (Open House Model) for Finished Medicinal Products in Hessian Consultation Hours (Ssb)